UNIVERSITA' CAMPUS BIO-MEDICO DI ROMA Via Álvaro del Portillo, 21 - 00128 Roma - Italia www.unicampus.it Antonio Nenna, MD Department of Cardiovascular.

Slides:



Advertisements
Similar presentations
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Advertisements

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Mitral valve. Repair vs. Replacement >%80 of MR are repairable Produces more physiological flow states It better preserves LV function Less thrombolic.
Can we prevent stent restenosis after coronary stent implantation
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
SURGICAL TREATMENT OF MODERATE ISCHEMIC MITRAL REGURGITATION: THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Robert E. Michler, M.D. For the CTSN Investigators.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Ventricular Diastolic Filling and Function
PCI VS CABG JOURNAL REVIEW
Open Repair of Ruptured Descending Thoracic and Thoracoabdominal Aortic Aneurysms in 100 Consecutive Cases Mario F. Gaudino, Christopher Lau, Monica Munjal,
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
AATS Grant Writing Workshop Developing a Clinical Research Program, Trial Design, Patient Enrollment Timothy J. Gardner MD Christiana Care Health System.
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
Echocardiographic predictors of perioperative atrial fibrillation EUROECHO 2010, Copenhagen, Denmark Katova T, Simova I, Nesheva A, Hristova K, Kostova.
Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
Intra-ventricular Papillary Muscle Head Approximation is Effective in Treating Ischemic MR in Dilated Ventricles - Comparison with Ring annuloplasty Muralidhar.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
+ Mitral Valve Prolapse A Surgeon’s Perspective Charles Anderson, M.D. Saint Joseph’s Hospital of Atlanta.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Clinical Trial Results. org Impact of Epicardial Anterior Fat Pad Retention on Postcardiothoracic Surgery Atrial Fibrillation Incidence: The AFIST-III.
Objective Bleeding events are grave and sometimes life threatening complications after prosthetic valve replacement, especially in hemodialysis patients.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Date of download: 11/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Targeted Left Ventricular Lead Placement to Guide.
Role of Device Therapy in FMR: Challenges and Opportunities
李孟霖, 蔡函衿, 陳瑞雄, 侯紹敏 國泰綜合醫院 心臟血管外科
Jeff Macemon MBChB, PDMSM Advanced Trainee, CTS
CTSN Trials of Mitral Valve Repair and Replacement
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
Functional MR: When to Intervene
Nishith Patel Waikato Cardiothoracic Unit Journal Club
Revascularization in Patients With Left Ventricular Dysfunction:
Structural and Functional Mitral Regurgitation:
EVEREST II 5-Year Report and Beyond
Benjamin B. Peeler, MD, Irving L. Kron, MD 
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
Valsartan in Acute Myocardial Infarction Trial Investigators
Cardiovacular Research Technologies
The American Heart Association
Ischemic Mitral Regurgitation
The STICH trial: Misguided conclusions
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Repair Techniques for Ischemic Mitral Regurgitation
Benjamin B. Peeler, MD, Irving L. Kron, MD 
Predicting recurrent mitral regurgitation after mitral valve repair: A difficult endeavor and a necessity  Denis Bouchard, MD, Louis P. Perrault, MD,
Questions and answers about the STICH trial: A different perspective
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Baseline left ventricular function and surgical annular stiffening to predict outcome and reverse left ventricular remodeling after undersized annuloplasty.
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Is subvalvular repair worthwhile in severe ischemic mitral regurgitation? Subanalysis of the Papillary Muscle Approximation trial  Francesco Nappi, MD,
Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial  Michael A. Acker, MD,
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Presentation transcript:

UNIVERSITA' CAMPUS BIO-MEDICO DI ROMA Via Álvaro del Portillo, Roma - Italia Antonio Nenna, MD Department of Cardiovascular Surgery Università Campus Bio-Medico di Roma, Rome, Italy American College of Cardiology 2016, 65 th Annual Scientific Session ACC.16, April , Chicago, USA Papillary Muscle Approximation versus Undersizing Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation: a Randomized Clinical Trial Francesco Nappi, Cristiano Spadaccio, Antonio Nenna, Mario Lusini, Christophe Acar, Massimo Chello

ISCHEMIC MITRAL REGURGITATION Ischemic mitral regurgitation (IMR) is a consequence of myocardial ischemia which results in geometrical disturbance of mitral valve due to papillary muscle injury and displacement, favoring impaired leaflet coaptation. The incidence of IMR among patients with myocardial infarction is up to 39% (1,6 – 2,8 million patients in the US) Functional regurgitation  imbalance closing forces VS tethering forces Circulation 1997;96: Circulation 2001;103: Am J Cardiol 2002;89:315-8

ISCHEMIC MITRAL REGURGITATION Tethering forces: annular dilatation enlargement of the LV chamber abnormal displacement of the PM with apical and lateral migration J Am Coll Cardiol 2003;42: Eur J Echocardiogr 2010;11: J Am Coll Cardiol 2014;63: Closing forces: reduction of LV contractility global LV dyssynchrony PM dyssynchrony altered systolic annular contraction

TREATMENT Severe ischemic mitral regurgitation Coronary revascularization + mitral valve surgery Mitral valve replacement Mitral valve repair (undersizing restrictive annuloplasty) “MV repair is associated with better short-term and long-term survival compared to MV replacement” CTSN trial (NEJM, Acker, Goldstein): “MV replacement is associated to reduced recurrence of MR and fewer heart-failure related cardiac events” J Am Coll Cardiol 2014;63: Eur J Cardiothorac Surg 2011;39: N Engl J Med 2014;370: N Engl J Med 2016;374:344-53

HOWEVER… Augmented leaflet tethering can be tempered by subvalvular procedures 1 A geometric disturbance requires a geometric correction MV repair approach should consider not only the mitral annulus, but also the subvalvular apparatus standard undersizing restrictive annuloplasty alone VS annular and subvalvular approach (restrictive annuloplasty + papillary muscle approximation) to investigate the relative role of papillary muscle surgery in IMR Preservation of PM function is associated with longer overall survival 2 Cardiac imaging confirmed the importance of subvalvular apparatus 3 1 Am J Cardiol 2010;106: Circulation 2012;126: JTCS 2014;148: JTCS 2012;143: Acta Cardiol 2013;68: JTCS 2004;128: Circulation 2010;122:S JTCS 2014;148:3252-4

STUDY DESIGN Final evaluation after 5 years from the surgical procedure (November 2015) PMARA

ENDPOINTS PRIMARY ENDPOINT: left ventricular remodeling LVEDD absolute difference from baseline, over a 5 years follow up SECONDARY ENDPOINTS Changes in echocardiographic parameters (EF, recurrent moderate-to-severe MR,…) Overall mortality Major adverse cardiac and cerebrovascular events (cardiac death, stroke, reintervention, hospitalization for heart failure, NYHA class worsening) Quality of life measures (Minnesota Living with Heart Failure, 12-item Short Form Health Survey, EuroQoL 5D) Circulation 1997;96: J Card Fail 2003;9: N Engl J Med 2009;361:

SURGICAL PROCEDURE PMA was performed using a 4 mm Gore-Tex tube encircling the PM bodies. Restrictive annuloplasty was performed using a Physioring (size 26 or 28 mm). Concomitant CABG was performed to achieve complete revascularization. The intraoperative goal: 25% reduction of the end-diastolic interpapillary distance compared to preoperative value (flax thread method). J Card Surg 2008;23:733-5

BASELINE CHARACTERISTICS RA N = 48 PMA N = 48 P value Age64.6± ± Previous myocardial infarction Inferior Antero-infero-posterior Antero-lateral Ring size N° 26 Ring size N° Number of grafts, mean ± ± Double IMA Cardiopulmonary bypass time108.1± ±9.2<0.001 Aortic cross clamp time93.4± ±9.9<0.001

LVEDD RAPMAP value Preoperative (number of patients) 61.4±3.7 (48) 62.7±3.4 (48) year55.4±3.2 (38) 56.0±3.1 (40) years56.3±4.1 (38) 56.4±3.6 (40) years60.6±4.6 (34) 56.5±5.7 (37) Change from baseline-0.2± ±4.1<0.001 Significant improvement in both groups In RA, progressive LV enlargement, values similar to pre-op PMA mantained the benefits achieved soon after surgery

EJECTION FRACTION Greater recovery of the LV function in the PMA group RAPMAP value Preoperative36.7±3.7%35.0±5.3% years39.9±3.9%44.1±6.0%<0.001 Change from baseline2.5±4.3%8.8±5.9%<0.001

RECURRENT MITRAL REGURGITATION Moderate-to-severe MRRAPMAP value 1 year 1 (2.6%) 3 (7.5%) years 5 (13.2%) 6 (15.0%) years 19 (55.9%) 10 (27.0%) Lower incidence of recurrent MR in the PMA group

OVERALL MORTALITY RAPMA P value In-hospital 4 (8.3%) 3 (6.2%) Cardiac-related 10 (20.8%) 8 (16.7%) Overall 14 (29.2%) 11 (22.9%) No differences in overall mortality

COMPOSITE CARDIAC END POINT RAPMAP value Rehospitalization NYHA worsening Reoperation Freedom from MACCEs was in favor of PMA in the last year of follow-up

MAIN FINDINGS 1)A decrease in LV dimension and an improvement in LV function in PMA, with stability of the ventricular diameters and a more effective recovery of the geometry of the MV (RA is not able to counteract or prevent the negative remodeling phenomenon occurring over time in IMR) 2)No significant differences in overall mortality and in the QoL 3)A reduced incidence of MACCEs in PMA group in the long-term (protective effect of papillary muscle surgery?) 4)A lower incidence of moderate-to-severe MR in the PMA group

Cardiothoracic Surgical Trials Network (CTSN) Trial Superiority of a MV replacement over its repair for recurrence of MR No significant between-group differences in LV reverse remodeling No significant differences in MACCEs, overall mortality or QoL Goldstein et al. reported a 2-year incidence of moderate-to-severe MR of 58.8%, while in our cohort it ranged between 13 and 15%. Can differences in baseline and operative characteristics account for different results ? N Engl J Med 2014;370: N Engl J Med 2016;374:344-53

Cardiothoracic Surgical Trials Network (CTSN) Trial N Engl J Med 2014;370: N Engl J Med 2016;374: CTSN Trial N = 251 PMA Trial N = 98 Mean age (years) Myocardial revascularization74-75% 100%, complete revascularization Previous procedures 20% CABG (redo) 35% PTCA 0% Baseline ejection fraction40±11 %36±6 % Annulus size – ring size (mean difference, mm) 3 (31.0 / 27.9) 10 (39.5 / 27.1) Long-term worse LV remodeling in CTSN Trial Better long-term outcomes in PMA Trial More heterogeneous patients in CTSN Trial Higher degree of retraction Reduced short-term MR recurrence in PMA Trial

The “Achilles heel” of MV repair in IMR is the long-term adverse LV remodeling, which influences the geometrical relationships within the ventricle and the equilibrium between forces. Papillary muscle surgery together with complete myocardial revascularization can address these issues improving the general negative outcomes of this procedure. Direct comparison of a “complete” MV repair strategy, including papillary muscle surgery, versus chordal-sparing mitral replacement should be advocated to define the best treatment in IMR CONCLUSION

PERSPECTIVES PM approximation may induce a geometrical “restraint effect” on the left ventricle: towards geometry-based biomechanical formulas (Fraldi M, Nappi F)

Grazie per l’attenzione ! ( Thank You for Your attention ! )